SEC Tracker
Get the app

Aibotics AIBT

Aibotics FY 2024: revenue $0

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Aibotics reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$0No year-earlier figure tagged10-K income statement, on EDGAR
  2. Net income−$1.8MAgainst −$1.2M in FY 202310-K income statement, on EDGAR
  3. Cash and cash equivalents$185K−34% from $279K in FY 202310-K balance sheet, on EDGAR
  4. Cash from operations−$259KAgainst −$107K in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Aibotics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2833 and related industry codes: the same peer list as the financial tables.

  1. Agentix AGTX public float $1M, Sep 30, 2025
  2. Galera Therapeutics GRTX public float $2M, Jun 30, 2025
  3. ProtoKinetix PKTX public float $2M, Jun 30, 2026
  4. Evofem Biosciences EVFM public float $1M, Jun 30, 2025
  5. Regen BioPharma RGBP public float $1M, Mar 31, 2025, over 18 months old